MacroGenics Inc at Barclays Global Healthcare Conference Transcript
Hi. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It's my great pleasure to introduce MacroGenics. With us today, we have Scott Koenig, CEO of MacroGenics. Scott, welcome.
And before we get into the Q&A, perhaps you could give us a high level introduction to the pipeline, therapeutic focus, technology focus and cash runway. Thank you.
Sure. Thank you, Peter, for the invitation today. So MacroGenics is a company focused on immune-based therapeutics for the treatment of cancer. We have developed proprietary technologies around the Fc domain of an antibody to enhance its activity to destroy tumors as well as a bispecific technology, which we call DART. Currently, we have 7 molecules in clinical development from Phase I to Phase III. I know we'll be talking about today, our lead asset that is under FDA review, following the BLA submission
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
